Timeline
GSK
GSK wins first global approval for hepatitis B drug Hibsago
GSK still needs wins in its drug pipeline says analyst
GSK's Bexsero booster filing accepted by EMA
GSK drops camlipixant after mixed phase III cough trial results
GSK completes Nuvalent acquisition, adding lung cancer drugs
GSK's Jemperli hits primary goal in rectal cancer trial
Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer
Deutsche Bank holds GSK at 1,900p as prescription tracker flags mixed product trends
GSK wins orphan drug status in US and Europe for momelotinib in rare inflammatory blood disorder with no approved treatments
GSK to buy Nuvalent for $10.6bn to add late‑stage lung‑cancer drugs
GSK posts positive Phase 3 results for Hepatitis B treatment
GSK lands expanded approval for RSV vaccine Arexvy in Japan
GSK strikes exclusive China collab to roll out bepirovirsen
GSK wins FDA priority review and breakthrough tag for bepirovirsen
GSK's efimosfermin sees FDA Breakthrough
GSK subsidiary TESARO has anticipatory breach claim dismissed by Delaware court
GSK wins China approval for Blenrep in 2L+ multiple myeloma
GSK completes acquisition of 35Pharma for $950m
GSK expands Arexvy approval to US adults 18–49 at increased risk
More in Pharma
Shield Therapeutics takes full US control of ACCRUFeR
The iron deficiency specialist will absorb its co-commercialisation partner's sales force and retain all US gross profit from ACCRUFeR, paying Viatris a royalty instead of a profit share.